INPP4B is an oncogenic regulator in human colon cancer

- Guo, S. T., Chi, M. N., Yan, X. G., Farrelly, M., Wang, F. H., Lai, F., Wang, J. F., Li, Y. P., Ackland, S., Scott, R., Agoulnik, I. U., Hondermarck, H., Yang, R. H., Thorne, R. F., Liu, T., Zhang, X. D., Jiang, C. C., Guo, X. Y., Zan, L. K., Wang, C. Y., Xi, Y. F., Jin, L., Croft, A., Tseng, H.-Y.

Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3

- Lai, F., Guo, S. T., Norman, J., Liu, T., Hersey, P., Zhang, X. D., Jin, L., Jiang, C. C., Wang, C. Y., Croft, A., Chi, M. N., Tseng, H-Y., Farrelly, M., Atmadibrata, B.

CAVATAK (Coxsackievirus A21) displays potent oncolytic activity in BRAFV600E mutant melanoma cells resistant to selective BRAF kinase inhibitors

- Shafren, D. R., Farrelly, M., Croft, A. J., Davies, B., Stewart, J., Ingham, R., Quah, M. Y., Au, G., Hersey, P.

Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma

- Hersey, Peter, Nguyen, T., Farrelly, M., Menzies, S.W., Hirst, D., Johnson, H., Coventry, B., Collins, S.